Mesalamine: profile and news

Salix Pharmaceuticals Reports 4Q2005 and FY2005 Results; 2005 ... Feb 24, 2006
XIFAXAN in four indications, a balsalazide tablet for the treatment of mildly to moderately active ulcerative colitis and granulated mesalamine for the ... - Genetic Engineering News,

Shire plc: Strong 2005 Performance Supports Positive Outlook Feb 23, 2006
...carbamazepine extended-release capsules) FOSRENOL(R) (lanthanum carbonate) GA-GCB(R) (gene-activated) LODINE (R) (etodolac) MESAVANCE(TM) (mesalamine) REMINYL(R ... - PR Newswire (press release),

Shire seeks approval for its ulcerative colitis drug in Europe Feb 10, 2006
As of 2003, mesalamine-based Asacol had a 60% share of ulcerative colitis drug market. The drug is coated with a pH-sensitive acrylic ... - In-PharmaTechnologist.com,

Shire Plc: Strong 2005 Performance Supports Positive Outlook Feb 23, 2006
Inc., the impact of the 500mg dosage form launched in the third quarter of 2004 and a 2% increase in the total US oral mesalamine prescription market. ... - International News Service,

CCFA Encourages Early, Frequent Colorectal Cancer Screenings for ... Mar 2, 2006
According to some experts, medications used to treat inflammation of the colon -- sulfasalazine (example: Azulfidine®) and mesalamine (examples: Asacol ... - EndoNurse,

Salix Pharmaceuticals to Present at Roth Capital Conference Feb 14, 2006
Salix markets COLAZAL(R), XIFAXAN(R), VISICOL(R), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). Granulated mesalamine, INKP-102 and NRL944 are under development. ... - Genetic Engineering News,

Antibe Therapeutics Receives $500,000 Commercialization Award from ... Feb 7, 2006
...presently on the market. The Company's lead drug is a derivative of mesalamine (5-aminosalicylic acid). Mr. Daniel Legault, President ... - CCNMatthews (press release),

Axcan announces record revenue of $70.6 million for the first ... Feb 9, 2006
CANASA / SALOFALK RECTAL GEL Axcan recently completed Phase III studies to confirm the efficacy and safety of a new mesalamine rectal gel in the treatment of ... - Canada NewsWire (press release),

Axcan announces record revenue of $70.6 million for the first ... Feb 9, 2006
Axcan recently completed Phase III studies to confirm the efficacy and safety of a new mesalamine rectal gel in the treatment of distal ulcerative colitis. ... - Yahoo! News (press release)

Axcan announces record revenue of $70.6 million for the first ... 09 Feb 2006
CANASA / SALOFALK RECTAL GEL Axcan recently completed Phase III studies to confirm the efficacy and safety of a new mesalamine rectal gel in the treatment of ... - PR Newswire (press release),

Salix Pharmaceuticals Development Update; XIFAXAN(R) Trials ... Jan 11, 2006
...of mildly to moderately active ulcerative colitis, and patient enrollment continues in two late-stage trials designed to evaluate granulated mesalamine for the ... - Business Wire (press release),

Salix Pharmaceuticals Announces 4Q2005 and FY2005 Financial ... Jan 31, 2006
Salix markets COLAZAL(R), XIFAXAN(R), VISICOL(R), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). Granulated mesalamine, INKP-102 and NRL944 are under development. ... - Genetic Engineering News,

Mild to Moderate Ulcerative Colitis Responds to Once-Daily ... Nov 8, 2005
...ulcerative colitis have higher rates of remission and improvement when treated with an investigative once-daily formulation of mesalamine, SPD476 (Mesavance ... - DG News

IBD: Current and Future Trends Dec 1, 2005
...four such cases. Mesalamine and budesonide are antiinflammatory drugs used to induce and maintain remission of IBD. 9 Both drug ... - EndoNurse,

Salix Pharmaceuticals Acquires Patent-Protected, Liquid Peg Bowel ... Dec 7, 2005
Granulated mesalamine and INKP-102 are under development. For full prescribing information on Salix products, please visit www.salix.com. ... - Genetic Engineering News,

Axcan reports fourth quarter and year-end 2005 financial results ... Nov 10, 2005
Axcan applied for a Supplemental New Drug Submission to the Therapeutic Products Directorate of Health Canada for a new 750-milligram mesalamine (5-ASA) tablet ... - Yahoo! News (press release)

Axcan reports fourth quarter and year-end 2005 financial results ... Nov 10, 2005
TABLETS Axcan applied for a Supplemental New Drug Submission to the Therapeutic Products Directorate of Health Canada for a new 750-milligram mesalamine (5-ASA ... - PR Newswire (press release),

Crohn's disease affects UF lifestyles Dec 2, 2005
Therapies that have already worked for Crohn's disease sufferers include mesalamine medicines that reduce bowel inflammation, oral steroid use and a diet that ... - Gainesville Sun,

Salix Pharmaceuticals Reports 3Q2005 Results Nov 8, 2005
The granulated mesalamine program that began during the fourth quarter of 2004 is ongoing in its evaluation of mesalamine for the maintenance of ulcerative ... - Business Wire (press release),

5-Aminosalicylic Acid and Risk of Colorectal Polyps in Patients ... Oct 21, 2005
When the researchers adjusted 5-ASA data for the specific medications used, the increased use was only significant for mesalamine. ... - DG News

Perrigo Company Reports First Quarter Fiscal 2006 Financial ... Oct 27, 2005
...sales of $29.1 million and operating income of $3.8 million, which included a charge of $2.8 million before-tax for the recall of mesalamine suspension product ... - PR Newswire (press release),

Salix Pharmaceuticals Announces 3Q2005 Financial Results ... Oct 25, 2005
Salix markets COLAZAL(R), XIFAXAN(R), VISICOL(R), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). A granulated mesalamine product also is under development. ... - Genetic Engineering News,

Salix Pharmaceuticals Completes Merger with InKine Pharmaceutical ... Oct 3, 2005
...mg). Granulated mesalamine is under development. Salix trades on the NASDAQ National Market under the ticker symbol "SLXP". For ... - Business Wire (press release),

SPD476 Phase II Study Results Presented at World Congress of ... Sep 13, 2005
Advanced Multi-Matrix System technology may allow for first once daily dosing of mesalamine in Ulcerative Colitis (UC), a form of Inflammatory Bowel Disease ... - PR Newswire (press release),

SPD476 Phase II Study Results Presented at World Congress of ... Sep 13, 2005
Results of a randomized, multi-center, double blind parallel group dose ranging study of an advanced formulation of high-strength mesalamine, SPD476, were ... - ArriveNet (press release),

Salix Pharmaceuticals to Present At UBS Conference Sep 21, 2005
Salix markets COLAZAL(R), XIFAXAN(R), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). A granulated mesalamine product also is under development. ... - Business Wire (press release),

Salix Pharmaceuticals to Present at Thomas Weisel Partners ... Sep 1, 2005
Salix markets COLAZAL(R), XIFAXAN(R), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). A granulated mesalamine product also is under development. ... - Business Wire (press release),

Axcan announces third quarter 2005 results Aug 11, 2005
SALOFALK 750 MG TABLETS - The Company filed a supplemental New Drug Submission ("sNDS") for approval of a new 750-milligram mesalamine (5-ASA) tablet for the ... - PR Newswire (press release),

Good' bacteria help ease pain of colitis Jul 30, 2005
The VSL#3 can be considered an important potential treatment for those patients who don't respond to conventional therapy such as mesalamine or 5ASA, Dr ... - I-Newswire.com (press release)

THE FAMILY DOCTOR Jul 19, 2005
Mesalamine, administered as a suppository, is the prescription drug of choice for mild ulcerative colitis limited to the end of the colon. ... - Newsday

Probiotic Bacteria Induce Remission of Active Ulcerative Colitis Jul 28, 2005
...therefore enrolled 34 patients with mild to moderate UC and a UC Disease Activity Index (UCDAI) score of 3-9. Treatment with mesalamine, corticosteroids, or ... - Medscape (subscription)

SHIRE PHARMACEUTICALS GROUP PLC: GOOD SECOND QUARTER RESULTS WITH ... Jul 28, 2005
...sales deductions. PENTASA had a 19% share of the total US oral mesalamine prescription market in June 2005 (June 2004: 17%). US ... - ITNews

Salix Pharmaceuticals Announces 2Q2005 Financial Results ... Jul 26, 2005
Salix markets COLAZAL(R), XIFAXAN(TM), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). A granulated mesalamine product also is under development. ... - Business Wire (press release)